Should You Buy Acorda Therapeutics Inc (ACOR)?

Consequently, specific money managers have been driving this bullishness. Point72 Asset Management, managed by Steve Cohen, assembled the most valuable position in Acorda Therapeutics Inc (NASDAQ:ACOR), worth an estimated $28.7 million at the end of the quarter. Matt Sirovich and Jeremy Mindich’s Scopia Capital also initiated a $15 million position during the quarter. The other funds with new positions in the stock are Hal Mintz’s Sabby Capital, Ken Greenberg and David Kim’s Ghost Tree Capital, and Peter Muller’s PDT Partners.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Acorda Therapeutics Inc (NASDAQ:ACOR) but similarly valued. We will take a look at CYS Investments Inc (NYSE:CYS), Government Properties Income Trust (NYSE:GOV), WestAmerica Bancorp. (NASDAQ:WABC), and Viper Energy Partners LP (NASDAQ:VNOM). All of these stocks’ market caps match ACOR’s market cap.

As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $25 million. CYS Investments Inc (NYSE:CYS) is the most popular stock in this table. On the other hand Viper Energy Partners LP (NASDAQ:VNOM) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Acorda Therapeutics Inc (NASDAQ:ACOR) is more popular among hedge funds and has also attracted investments far exceeding the average of this group: $203 million at the end of the third quarter. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.